Long-Term Follow-Up for Mortality and Cancer in a Randomized Placebo-Controlled Trial of Vitamin D3 and/or Calcium (RECORD Trial)

Research output: Contribution to journalArticle

Standard

Long-Term Follow-Up for Mortality and Cancer in a Randomized Placebo-Controlled Trial of Vitamin D3 and/or Calcium (RECORD Trial). / Avenell, A; Maclennan, GS; Jenkinson, David; McPherson, GC; McDonald, AM; Pant, PR; Grant, AM; Campbell, MK; Anderson, FH; Cooper, C; Francis, RM; Gillespie, WJ; Robinson, CM; Torgerson, DJ; Wallace, WA.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 97, No. 2, 01.02.2012, p. 614-622.

Research output: Contribution to journalArticle

Harvard

Avenell, A, Maclennan, GS, Jenkinson, D, McPherson, GC, McDonald, AM, Pant, PR, Grant, AM, Campbell, MK, Anderson, FH, Cooper, C, Francis, RM, Gillespie, WJ, Robinson, CM, Torgerson, DJ & Wallace, WA 2012, 'Long-Term Follow-Up for Mortality and Cancer in a Randomized Placebo-Controlled Trial of Vitamin D3 and/or Calcium (RECORD Trial)', Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 2, pp. 614-622. https://doi.org/10.1210/jc.2011-1309

APA

Avenell, A., Maclennan, GS., Jenkinson, D., McPherson, GC., McDonald, AM., Pant, PR., Grant, AM., Campbell, MK., Anderson, FH., Cooper, C., Francis, RM., Gillespie, WJ., Robinson, CM., Torgerson, DJ., & Wallace, WA. (2012). Long-Term Follow-Up for Mortality and Cancer in a Randomized Placebo-Controlled Trial of Vitamin D3 and/or Calcium (RECORD Trial). Journal of Clinical Endocrinology and Metabolism, 97(2), 614-622. https://doi.org/10.1210/jc.2011-1309

Vancouver

Author

Avenell, A ; Maclennan, GS ; Jenkinson, David ; McPherson, GC ; McDonald, AM ; Pant, PR ; Grant, AM ; Campbell, MK ; Anderson, FH ; Cooper, C ; Francis, RM ; Gillespie, WJ ; Robinson, CM ; Torgerson, DJ ; Wallace, WA. / Long-Term Follow-Up for Mortality and Cancer in a Randomized Placebo-Controlled Trial of Vitamin D3 and/or Calcium (RECORD Trial). In: Journal of Clinical Endocrinology and Metabolism. 2012 ; Vol. 97, No. 2. pp. 614-622.

Bibtex

@article{7f023d90621048b8b3d01703e780f775,
title = "Long-Term Follow-Up for Mortality and Cancer in a Randomized Placebo-Controlled Trial of Vitamin D3 and/or Calcium (RECORD Trial)",
abstract = "Context: Vitamin D or calcium supplementation may have effects on vascular disease and cancer. Objective: Our objective was to investigate whether vitamin D or calcium supplementation affects mortality, vascular disease, and cancer in older people. Design and Setting: The study included long-term follow-up of participants in a two by two factorial, randomized controlled trial from 21 orthopedic centers in the United Kingdom. Participants: Participants were 5292 people (85% women) aged at least 70 yr with previous low-trauma fracture. Interventions: Participants were randomly allocated to daily vitamin D(3) (800 IU), calcium (1000 mg), both, or placebo for 24-62 months, with a follow-up of 3 yr after intervention. Main Outcome Measures: All-cause mortality, vascular disease mortality, cancer mortality, and cancer incidence were evaluated. Results: In intention-to-treat analyses, mortality [hazard ratio (HR) = 0.93; 95% confidence interval (CI) = 0.85-1.02], vascular disease mortality (HR = 0.91; 95% CI = 0.79-1.05), cancer mortality (HR = 0.85; 95% CI = 0.68-1.06), and cancer incidence (HR = 1.07; 95% CI = 0.92-1.25) did not differ significantly between participants allocated vitamin D and those not. All-cause mortality (HR = 1.03; 95% CI = 0.94-1.13), vascular disease mortality (HR = 1.07; 95% CI = 0.92-1.24), cancer mortality (HR = 1.13; 95% CI = 0.91-1.40), and cancer incidence (HR = 1.06; 95% CI = 0.91-1.23) also did not differ significantly between participants allocated calcium and those not. In a post hoc statistical analysis adjusting for compliance, thus with fewer participants, trends for reduced mortality with vitamin D and increased mortality with calcium were accentuated, although all results remain nonsignificant. Conclusions: Daily vitamin D or calcium supplementation did not affect mortality, vascular disease, cancer mortality, or cancer incidence.",
author = "A Avenell and GS Maclennan and David Jenkinson and GC McPherson and AM McDonald and PR Pant and AM Grant and MK Campbell and FH Anderson and C Cooper and RM Francis and WJ Gillespie and CM Robinson and DJ Torgerson and WA Wallace",
year = "2012",
month = feb,
day = "1",
doi = "10.1210/jc.2011-1309",
language = "English",
volume = "97",
pages = "614--622",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "Endocrine Society",
number = "2",

}

RIS

TY - JOUR

T1 - Long-Term Follow-Up for Mortality and Cancer in a Randomized Placebo-Controlled Trial of Vitamin D3 and/or Calcium (RECORD Trial)

AU - Avenell, A

AU - Maclennan, GS

AU - Jenkinson, David

AU - McPherson, GC

AU - McDonald, AM

AU - Pant, PR

AU - Grant, AM

AU - Campbell, MK

AU - Anderson, FH

AU - Cooper, C

AU - Francis, RM

AU - Gillespie, WJ

AU - Robinson, CM

AU - Torgerson, DJ

AU - Wallace, WA

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Context: Vitamin D or calcium supplementation may have effects on vascular disease and cancer. Objective: Our objective was to investigate whether vitamin D or calcium supplementation affects mortality, vascular disease, and cancer in older people. Design and Setting: The study included long-term follow-up of participants in a two by two factorial, randomized controlled trial from 21 orthopedic centers in the United Kingdom. Participants: Participants were 5292 people (85% women) aged at least 70 yr with previous low-trauma fracture. Interventions: Participants were randomly allocated to daily vitamin D(3) (800 IU), calcium (1000 mg), both, or placebo for 24-62 months, with a follow-up of 3 yr after intervention. Main Outcome Measures: All-cause mortality, vascular disease mortality, cancer mortality, and cancer incidence were evaluated. Results: In intention-to-treat analyses, mortality [hazard ratio (HR) = 0.93; 95% confidence interval (CI) = 0.85-1.02], vascular disease mortality (HR = 0.91; 95% CI = 0.79-1.05), cancer mortality (HR = 0.85; 95% CI = 0.68-1.06), and cancer incidence (HR = 1.07; 95% CI = 0.92-1.25) did not differ significantly between participants allocated vitamin D and those not. All-cause mortality (HR = 1.03; 95% CI = 0.94-1.13), vascular disease mortality (HR = 1.07; 95% CI = 0.92-1.24), cancer mortality (HR = 1.13; 95% CI = 0.91-1.40), and cancer incidence (HR = 1.06; 95% CI = 0.91-1.23) also did not differ significantly between participants allocated calcium and those not. In a post hoc statistical analysis adjusting for compliance, thus with fewer participants, trends for reduced mortality with vitamin D and increased mortality with calcium were accentuated, although all results remain nonsignificant. Conclusions: Daily vitamin D or calcium supplementation did not affect mortality, vascular disease, cancer mortality, or cancer incidence.

AB - Context: Vitamin D or calcium supplementation may have effects on vascular disease and cancer. Objective: Our objective was to investigate whether vitamin D or calcium supplementation affects mortality, vascular disease, and cancer in older people. Design and Setting: The study included long-term follow-up of participants in a two by two factorial, randomized controlled trial from 21 orthopedic centers in the United Kingdom. Participants: Participants were 5292 people (85% women) aged at least 70 yr with previous low-trauma fracture. Interventions: Participants were randomly allocated to daily vitamin D(3) (800 IU), calcium (1000 mg), both, or placebo for 24-62 months, with a follow-up of 3 yr after intervention. Main Outcome Measures: All-cause mortality, vascular disease mortality, cancer mortality, and cancer incidence were evaluated. Results: In intention-to-treat analyses, mortality [hazard ratio (HR) = 0.93; 95% confidence interval (CI) = 0.85-1.02], vascular disease mortality (HR = 0.91; 95% CI = 0.79-1.05), cancer mortality (HR = 0.85; 95% CI = 0.68-1.06), and cancer incidence (HR = 1.07; 95% CI = 0.92-1.25) did not differ significantly between participants allocated vitamin D and those not. All-cause mortality (HR = 1.03; 95% CI = 0.94-1.13), vascular disease mortality (HR = 1.07; 95% CI = 0.92-1.24), cancer mortality (HR = 1.13; 95% CI = 0.91-1.40), and cancer incidence (HR = 1.06; 95% CI = 0.91-1.23) also did not differ significantly between participants allocated calcium and those not. In a post hoc statistical analysis adjusting for compliance, thus with fewer participants, trends for reduced mortality with vitamin D and increased mortality with calcium were accentuated, although all results remain nonsignificant. Conclusions: Daily vitamin D or calcium supplementation did not affect mortality, vascular disease, cancer mortality, or cancer incidence.

U2 - 10.1210/jc.2011-1309

DO - 10.1210/jc.2011-1309

M3 - Article

C2 - 22112804

VL - 97

SP - 614

EP - 622

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -